New Jersey 2026-2027 Regular Session

New Jersey Senate Bill S4030

Introduced
3/19/26  

Caption

Designates minimum percentage of residential substance use disorder treatment facility beds for use by NJ FamilyCare eligible individuals as condition for licensure.

Summary

S4030 would require residential substance use disorder treatment facilities seeking licensure from the Department of Health to reserve at least 40 percent of their beds for NJ FamilyCare-eligible individuals. For newly licensed facilities, the required utilization rate must be reached within 12 months of initial licensure and then maintained. For facilities already operating under a state license, the same 40 percent threshold would have to be met within 12 months of the next license renewal after the bill takes effect, with continued compliance required thereafter. The bill also gives the Department of Health enforcement authority by withholding an initial license from a new facility, or refusing to renew an existing facility’s license, until the facility documents compliance with the bed-percentage requirement. The bill defines the covered facilities broadly to include halfway houses, extended care facilities, long-term and short-term residential facilities, and similar substance use disorder treatment settings, including hospital-based and non-hospital-based detoxification services in a structured recovery environment.

Impact

This bill would amend the licensing conditions for residential substance use disorder treatment facilities under New Jersey law by adding a payer-mix or bed-reservation requirement tied to NJ FamilyCare, the state Medicaid and CHIP program. It would affect both new applicants and currently licensed facilities, and would give the Department of Health a direct compliance lever through initial licensure and renewal decisions. The practical effect would be to increase access to residential addiction treatment for NJ FamilyCare beneficiaries and to require providers in this sector to adjust admissions and bed allocation practices to meet the mandated threshold.

Sentiment

Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears policy-driven and supportive of expanding access to treatment for publicly insured individuals. The measure is framed as a licensure condition rather than a funding program, suggesting an intent to ensure that state-regulated treatment capacity is available to NJ FamilyCare enrollees. No formal opposition, amendments, or recorded vote history is provided in the context, so there is no documented public controversy in the supplied record.

Contention

The main point of contention likely concerns the mandated 40 percent bed set-aside and whether it could be difficult for facilities to meet while maintaining financial viability, especially for providers that rely heavily on private-pay or commercial insurance patients. Facilities may also object to the administrative burden of tracking and maintaining compliance, and to the possibility that licensure could be delayed or denied for failure to meet the threshold. Supporters would likely emphasize improved access for low-income and publicly insured individuals, while critics may argue the requirement could discourage new facility development or reduce operational flexibility.

Companion Bills

NJ S4019

Carry Over Designates minimum percentage of residential substance use disorder treatment facility beds for use by NJ FamilyCare eligible individuals as condition for licensure.

Similar Bills

NJ S1792

Establishes program to subsidize purchase price of medical cannabis for registered qualifying patients enrolled in Medicaid or NJ FamilyCare programs.

NJ S560

Establishes pilot program to refer certain emergency department patients for development of coordinated behavioral health care treatment and support services plan.

NJ A3570

Establishes pilot program to refer certain emergency department patients for development of coordinated behavioral health care treatment and support services plan.

NJ S2918

Requires prescription drug coverage for serious mental illness without prior authorization or utilization management, including step therapy.

NJ A4694

Requires prescription drug coverage for serious mental illness without prior authorization or utilization management, including step therapy.

NJ A2479

Permits clinical laboratories to provide certain patients discounts without affecting NJ FamilyCare reimbursement rates or violating NJ FamilyCare rebate prohibitions.

NJ S1399

Permits clinical laboratories to provide certain patients discounts without affecting NJ FamilyCare reimbursement rates or violating NJ Familycare rebate prohibitions.

NJ SCR81

Requests President and Congress take action to permit federal Medicaid funding for certain substance use disorder programs.